North America and Europe Women's Health Market, By Treatment (Drugs and Device), Indication (Cancer, Reproductive Health, Urological Disorders, Hypothyroidism, Post-Menopausal Syndrome, and Others), Delivery Mode (Prescription and Over the Counter), Drug Type (Branded and Generic), Care Type (General Healthcare & Wellness, Pregnancy & Nursing Care, Pelvic & Uterine Healthcare, and Others), End User (Hospitals and Clinics, Gynecology Centers, Homecare Settings, Research Institutes, and Others), Distribution Channel (Direct Tenders, Retail Sales, Online Sales, and Others) - Industry Trends and Forecast to 2031.
North America and Europe Women’s Health Market Analysis and Size
Rising rates of chronic debilitating conditions among women and changing lifestyles & environmental factors impacting health are some of the drivers boosting the demand in the market. Also, the government initiatives to improve overall health and wellbeing is further propelling the market growth. The major restraint which is impacting the market is the adverse effects associated with certain products. The increasing awareness and acceptance of fertility treatments is acting as an opportunity for the market growth. The high maternal mortality and morbidity is acting as challenge for the market growth.
North America and Europe women’s health market is expected to reach USD 16.49 billion by 2031, from USD 9.12 billion in 2023, growing at the CAGR of 8.0% in the forecast period of 2024 to 2031.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016–2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Treatment (Drugs and Device), Indication (Cancer, Reproductive Health, Urological Disorders, Hypothyroidism, Post-Menopausal Syndrome, and Others), Delivery Mode (Prescription and Over the Counter), Drug Type (Branded and Generic), Care Type (General Healthcare & Wellness, Pregnancy & Nursing Care, Pelvic & Uterine Healthcare, and Others), End User (Hospitals and Clinics, Gynecology Centers, Homecare Settings, Research Institutes, and Others), Distribution Channel (Direct Tenders, Retail Sales, Online Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, U.K., and Rest of Europe
|
|
Market Players Covered
|
Lilly, Abbott, Lupin, GSK plc., Novartis AG, AbbVie Inc., Noven Pharmaceuticals, Inc., Vertical Pharmaceuticals, LLC, Veru Inc., and Pfizer Inc. among others
|
Market Definition
The area of medicine and healthcare services known as "women's health" is committed towards the particular biological, physiological, and psychological requirements and problems that affect women at all stages of life. It covers a range of topics related to women-specific wellness promotion, gynaecological care, reproductive health, and sexual health. Also, gender-specific health issues related to menstruation, contraception, pregnancy, childbirth, menopause, and diseases such as osteoporosis, endometriosis, breast cancer, and ovarian cancer are covered under women's health. Women's health also places a strong emphasis on screenings, preventative care, and interventions meant to close the gender gaps in healthcare outcomes, access, and quality.
North America and Europe Women’s Health Market Dynamics
This section deals with understanding the market drivers, opportunities, challenges, and restraints. All of this is discussed in detail below:
Drivers
- Rising Rates of Chronic Debilitating Conditions among Women
The ageing population is a major factor contributing to the rising incidence of chronic diseases among women in North America and Europe. Women are more likely than men to experience age-related illnesses such diabetes, osteoporosis, cardiovascular disease, and some types of cancer. The increasing number of women-specific medical conditions is driving up demand for novel diagnostic techniques, therapeutic approaches, and preventive measures that target early identification, efficient treatment, and favorable outcomes. Healthcare providers, pharmaceutical companies, and makers of medical devices are responding to this need by increasing their investments in R&D to better satisfy the changing demands of women. It is done by broadening their product offerings, and improving healthcare delivery models.
Mitigating the impact of chronic diseases on women's health outcomes in North America and Europe requires public health measures that address social determinants of health, improve access to healthcare services, and promote healthy behaviors. Healthcare institutions, legislators, researchers, and communities must work together to address diseases including osteoporosis, endometriosis, breast cancer, and ovarian cancer, which continue to impact women globally. Thus, the rising rates of chronic debilitating conditions among women is a major driver for the market growth.
- Innovative Technologies being Developed as an Aftermath of R&D Activities
The field of women's healthcare is changing as a result of revolutionary developments in medical technology, which are providing innovative solutions to the diagnosis, treatment, and management of a variety of disorders. These developments cover a wide range of technology, such as targeted medicines, minimally invasive surgical methods, precision medicine, and regenerative medicine strategies.
The demand for specialized healthcare services, collaboration between healthcare providers, academics, and technology developers, and investment in infrastructure and workforce development are all being fueled by the acceptance of these new treatments.
The incorporation of digital health technology, including mobile health apps, telemedicine, and remote monitoring, is improving access to care and enabling women to take an active role in healthcare industry. As a result, the women's health market is expanding quickly and innovating throughout North America and Europe. New technologies are facilitating advances in patient outcomes, treatment quality, and the delivery of healthcare as a whole. Thus, the innovative technologies being developed as an aftermath of R&D activities is propelling the market growth.
Opportunity
- Increasing Recognition for Mental Health
Mental health issues, including depression, anxiety, postpartum depression, and eating disorders, disproportionately affect women, often due to a combination of biological, psychological, and social factors. This heightened awareness of mental health challenges has increased demand for innovative therapies, digital mental health tools, and support services tailored specifically to women's unique needs.
Therefore, in response to this demand, companies specializing in women's mental health have an opportunity to develop and offer a range of solutions aimed at improving mental well-being and addressing mental health disorders among women.
Digital mental health tools, and support services tailored to women's specific needs, stakeholders in the market can contribute to improving mental health outcomes and enhancing the quality of life for women across diverse communities. This is done by investing in the development of innovative therapies. The growing recognition of the importance of mental health and well-being among women in North America and Europe presents a significant opportunity for the market growth.
Restraints/Challenges
- Adverse Effects Associated with Certain Products
Concerns regarding the efficacy and safety of a range of products aimed at women's health, such as personal care items, medical devices, and medications, have surfaced in recent years. Consumers, healthcare practitioners, and regulatory organizations are alarmed about the side effects of these products, which include hormone replacement treatment, contraceptive methods, and cosmetic surgeries.
Adverse consequences from drug use on women's health are common, which emphasizes the value of close observation, informed consent, and individualized treatment plans. Healthcare professionals need to carefully weigh the advantages and disadvantages of pharmaceutical therapies, taking into account the patient's preferences as well as their age, medical history, and comorbidities. Thus, the adverse effects associated with certain products is expected to restrain the market growth.
- Environmental Exposure Impacting Reproductive Health
Environmental exposures pose a significant challenge to women's reproductive health in North America and Europe due to industrialization, urbanization, and widespread chemical use in agriculture, manufacturing, and consumer products. Exposure to endocrine-disrupting chemicals (EDCs) such as BPA, phthalates, and pesticides, found in plastics and personal care items, can lead to infertility, menstrual irregularities, and hormonal imbalances. Air pollution from industrial emissions and vehicle exhaust contributes to adverse pregnancy outcomes such as preterm birth and low birth weight. Stakeholders in the women's health market can mitigate risks and safeguard reproductive health for women across diverse communities. It can be done by raising awareness, implementing preventive measures, and advocating for policies to reduce environmental pollution. Environmental exposures impacting reproductive health represent a multifaceted challenge for the market growth.
Recent Developments
- In November 2023, Lupin entered into an exclusive partnership with Amman Pharmaceuticals Industries (Amman Pharma), a prominent pharmaceutical manufacturer with a presence in the MENA region and various global markets. This collaboration involves the marketing and commercialization rights for Ranibizumab, a biosimilar of Lucentis. This strategic partnership allows Lupin to tap into new regions and expand its market presence, ultimately enhancing the company's position in the pharmaceutical industry
- In July 2023, GSK plc. announced that the U.S. Food and Drug Administration (FDA) approved Jemperli (dostarlimab) as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test. This helped the company to expand its product offering
- In August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a once-daily, single-pill therapy for the management of moderate to severe pain associated with endometriosis in premenopausal women. The treatment course may last up to 24 months. This helped the company to expand its product range
- In November 2020, Avion Pharmaceuticals (subsidiary of Alora Pharmaceuticals, LLC), LLC, a specialty pharmaceutical firm, has secured an exclusive license and commercialization agreement with Aspen Pharma USA Inc. and Aspen Global Incorporated. This agreement grants Avion exclusive rights to relaunch Cenestin (synthetic conjugated estrogens, A) tablet, the sole plant-derived blend of nine conjugated estrogens
- In June 2020, AbbVie Inc. in collaboration with Neurocrine Biosciences, Inc., has announced that the U.S. Food and Drug Administration (FDA) has granted approval for ORIAHNN (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), allowing for a treatment duration of up to 24 months. ORIAHNN marks the inaugural FDA-approved non-surgical, oral treatment option for addressing heavy menstrual bleeding linked to uterine fibroids in pre-menopausal women. This approval expandsthe company’s portfolio of women's health medications and establishes Neurocrine Biosciences as a key player in the field
North America and Europe Women’s Health Market Scope
The North America and Europe women’s health market is categorized into seven notable segments which are based on treatment, indication, delivery mode, drug type, care type, end user, and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Treatment
- Drugs
- Device
On the basis of treatment, the North America and Europe women’s health market is segmented into drugs and device.
Indication
- Cancer
- Reproductive Health
- Urological Disorders
- Hypothyroidism
- Post-Menopausal Syndrome
- Others
On the basis of indication, the North America and Europe women’s health market is segmented into cancer, reproductive health, urological disorders, hypothyroidism, post-menopausal syndrome, and others.
Delivery Mode
- Prescription
- Over the Counter
On the basis of delivery mode, the North America and Europe women’s health market is segmented into prescription and over the counter.
Drug Type
- Branded
- Generic
On the basis of drug type, the North America and Europe women’s health market is segmented into branded and generic.
Care Type
- General Healthcare & Wellness
- Pregnancy & Nursing Care
- Pelvic & Uterine Healthcare
- Others
On the basis of care type, the North America and Europe women’s health market is segmented into general healthcare & wellness, pregnancy & nursing care, pelvic & uterine healthcare, and others.
End User
- Hospitals and Clinics
- Gynecology Centers
- Homecare Settings
- Research Institutes
- Others
On the basis of end user, the North America and Europe women’s health market is segmented into hospitals and clinics, gynecology centers, homecare settings, research institutes, and others.
Distribution Channel
- Direct Tenders
- Retail Sales
- Online Sales
- Others
On the basis of distribution channel, the North America and Europe women’s health market is segmented into direct tenders, retail sales, online sales, and others.
The North America and Europe Women’s Health Market Regional Analysis/Insights
The North America and Europe women’s health market is categorized into seven notable segments which are based on treatment, indication, delivery mode, drug type, care type, end user, and distribution channel.
The countries covered in the market is U.S., Canada, Mexico, Germany, France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, U.K., and rest of Europe.
North America is expected to dominate the North America and Europe women’s health market as innovative technologies being developed as an aftermath of R&D activities in the region. The U.S. is expected to dominate the North America women’s health market due to the presence of advanced healthcare infrastructure and technological innovation for women’s healthcare sector. Germany is expected to dominate the Europe women’s health market due to their strong presence in international market with extensive distribution network.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data point downstream and upstream value chain analysis, technical trends porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
North America and Europe Women’s Health Market Share Analysis
The North America and Europe women’s health market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to the market.
Some of the major market players operating in the North America and Europe women’s health market are Lilly, Abbott, Lupin, GSK plc., Novartis AG, AbbVie Inc., Noven Pharmaceuticals, Inc., Vertical Pharmaceuticals, LLC, Veru Inc., and Pfizer Inc. among others.
SKU-